Wall Street analysts predict that Voyager Therapeutics Inc (NASDAQ:VYGR) will post earnings per share of ($0.72) for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Voyager Therapeutics’ earnings. The highest EPS estimate is ($0.48) and the lowest is ($0.92). Voyager Therapeutics posted earnings of ($0.57) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 26.3%. The firm is expected to announce its next quarterly earnings report before the market opens on Wednesday, March 14th.
On average, analysts expect that Voyager Therapeutics will report full year earnings of ($2.98) per share for the current financial year, with EPS estimates ranging from ($3.20) to ($2.74). For the next fiscal year, analysts expect that the business will report earnings of ($3.03) per share, with EPS estimates ranging from ($4.16) to ($1.98). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side analysts that cover Voyager Therapeutics.
Several equities research analysts recently issued reports on the company. Zacks Investment Research upgraded Voyager Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, January 6th. Wedbush upped their price target on Voyager Therapeutics from $22.00 to $29.00 and gave the stock an “outperform” rating in a report on Wednesday, February 21st. Morgan Stanley upped their price target on Voyager Therapeutics from $36.00 to $39.00 and gave the stock an “overweight” rating in a report on Wednesday, February 21st. Canaccord Genuity reiterated a “buy” rating and set a $26.00 price target on shares of Voyager Therapeutics in a report on Tuesday, January 23rd. Finally, BidaskClub upgraded Voyager Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, January 5th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and nine have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $29.20.
In other Voyager Therapeutics news, insider Bernard Ravina sold 2,451 shares of the company’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $18.24, for a total value of $44,706.24. Following the completion of the transaction, the insider now owns 4,902 shares in the company, valued at approximately $89,412.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Dinah Ph.D. Sah sold 15,623 shares of the company’s stock in a transaction on Tuesday, February 27th. The shares were sold at an average price of $30.00, for a total value of $468,690.00. Following the completion of the transaction, the insider now owns 140,872 shares of the company’s stock, valued at approximately $4,226,160. The disclosure for this sale can be found here. Insiders sold a total of 21,704 shares of company stock valued at $572,928 in the last 90 days. Corporate insiders own 8.00% of the company’s stock.
Hedge funds have recently bought and sold shares of the company. Thompson Davis & CO. Inc. grew its stake in shares of Voyager Therapeutics by 67.7% during the 4th quarter. Thompson Davis & CO. Inc. now owns 7,485 shares of the company’s stock worth $124,000 after acquiring an additional 3,021 shares during the period. MetLife Investment Advisors LLC bought a new position in shares of Voyager Therapeutics during the 4th quarter worth $128,000. Goldman Sachs Group Inc. grew its stake in shares of Voyager Therapeutics by 8.9% during the 2nd quarter. Goldman Sachs Group Inc. now owns 17,048 shares of the company’s stock worth $153,000 after acquiring an additional 1,399 shares during the period. Teachers Advisors LLC grew its stake in shares of Voyager Therapeutics by 24.7% during the 2nd quarter. Teachers Advisors LLC now owns 25,685 shares of the company’s stock worth $230,000 after acquiring an additional 5,081 shares during the period. Finally, California State Teachers Retirement System grew its stake in shares of Voyager Therapeutics by 8.4% during the 2nd quarter. California State Teachers Retirement System now owns 25,811 shares of the company’s stock worth $231,000 after acquiring an additional 2,000 shares during the period. Institutional investors own 80.03% of the company’s stock.
TRADEMARK VIOLATION WARNING: This story was originally posted by Markets Daily and is the sole property of of Markets Daily. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://www.themarketsdaily.com/2018/03/13/brokerages-anticipate-voyager-therapeutics-inc-vygr-to-post-0-72-earnings-per-share.html.
About Voyager Therapeutics
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.